Identified as a Cardiology Fellow at Duke University Medical Center. (2023-2024)
As of 2024 · Last known relationship
Mohammad Shahzeb Khan is a physician-researcher whose work connects heart-failure prevention and treatment with the practical barriers patients face. Identified as an MD, MSc, he was a Duke University Medical Center Cardiology Fellow in 2023-2024, when a fellowship listing placed him at Baylor Scott & White Heart Hospital in Dallas. A 2025 report identified him as an assistant professor of medicine at Baylor College of Medicine. His research and presentations have examined socioeconomic factors, financial toxicity, and access to heart-failure therapies, as well as screening for heart-failure risk in people with type 2 diabetes. He has also addressed cardiometabolic treatment effects, dialysis statin uncertainty, and clinical outcomes in complex cardiovascular populations. He is identified as a co-founder of the Research Council of Pakistan and has given Duke Cardiology Grand Rounds on heart-failure prevention.
The fellowship alumni listing gives Baylor Scott & White Heart Hospital in Dallas, Texas as his listed location.
Each topic is linked to its supporting source in Sources.
Training includes Listed as a 2023-2024 alumnus and Fellow of the Duke Cardiovascular Disease Fellowship., Identified as a Cardiology Fellow at Duke University Medical Center. (2023-2024), Presented on socioeconomic barriers, access, and affordability in heart failure at the 82nd Scientific Sessions., and Identified with an MD degree., plus 4 more records.
Explore education and trainingAs of 2024
As of 2024
As of 2022
Co-authored an article titled “Rethinking Statins in Dialysis: Evidence of Absence or Clinical Equipoise?” with Tariq Shafi.[6]
2025
Discussed the impact of socioeconomic factors, financial toxicity, and access barriers on heart failure outcomes and therapies.[4]
2022
Presented pooled cohort analysis comparing methods for measuring heart failure risk in patients with type 2 diabetes without atherosclerotic cardiovascular disease.[5]